EpiGentek CRISPR/Cas9 SaCas9 Monoclonal Antibody [6H4]

EpiGentek has released a monoclonal antibody that is specific to Staphylococcus aureus Cas9 (SaCas9) and enables easy and specific monitoring of gene editing processes.

The CRISPR/Cas9 system allows for sequence-specific cleavage of a targeted genomic locus by delivering the RNA-guided Cas9 nuclease and appropriate guide RNAs into a cell. In addition, the protospacer adjacent motif (PAM) sequence immediately following the specificity sequence is necessary for successful binding of the Cas9 nuclease.

It is important to monitor the level of Cas9 editing protein or track the Cas9 editing protein in transfected cells, as it will show transfection efficiency and optimise the editing process in the total cell population. SaCas9-mediated genome editing has been reported in human cells and Arabidopsis. Because SaCas9 (1053 a.a.) is smaller than Streptococcus pyogenes Cas9 (SpCas9) (1368 a.a.), SaCas9 could have advantages for delivering and expressing Cas9 protein, especially using virus vectors.